Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.

Arch Dermatol 2002 Jun;138(6):799-802

Department of Dermatology, Massachusetts General Hospital, Boston, MA 02114, USA.

Background: Reports of vitiligo associated with metastases and rare cases of spontaneous regression of disease have fueled enthusiasm for immunologic approaches to the treatment of advanced melanoma. More recent strategies have focused on using antigen-presenting dendritic cells as vaccines.

Observations: We observed 3 cases of leukoderma associated with a novel adenovirus-mediated gp100/MART-1-transduced dendritic cell (MART indicates melanoma antigen recognized by T cells). All 3 patients had advanced metastatic melanoma. Despite the development of this leukodermic response, all patients experienced disease progression while under treatment.

Conclusion: We provide the initial evidence for effective induction of a leukodermic response with a gp100/MART-1-transduced dendritic cell vaccine.

Download full-text PDF

Source
http://dx.doi.org/10.1001/archderm.138.6.799DOI Listing
June 2002
5 Reads

Publication Analysis

Top Keywords

dendritic cell
12
gp100/mart-1-transduced dendritic
12
adenovirus-mediated gp100/mart-1-transduced
8
metastatic melanoma
8
cell vaccine
8
leukodermic response
8
leukoderma associated
4
associated novel
4
cell mart
4
antigen recognized
4
melanoma antigen
4
indicates melanoma
4
mart indicates
4
novel adenovirus-mediated
4
vaccinesobservations observed
4
strategies focused
4
melanoma strategies
4
advanced melanoma
4
treatment advanced
4
focused antigen-presenting
4

Similar Publications